Scholarlink

<p>High dose chemotherapy followed by autologous hematopoietic stem cell transplantation (ASCT) is the standard of care for relapsed or refractory diffuse large B-cell lymphoma (DLBCL). Rituximab has significantly improved outcomes of DLBCL patients when incorporated into first-line or second-line chemotherapy. However, whether its addition to conditioning regimens further improves efficacy remains controversial. In this study, we explored the efficacy and safety of Rituximab with CEAC conditioning, a regimen previously reported by our center. We compared the CEAC regimen with or without Rituximab in 80 DLBCL patients with propensity score matching method at a ratio of 1:1 (40 CEAC, 40 R-CEAC). The objective response rate (ORR) was 95% in the CEAC cohort compared to 93% in the R-CEAC cohort (<i>P</i> = 0.615). The complete response (CR) rate was 70% versus 60%, respectively (<i>P</i> = 0.348). The 3-year progression-free survival (PFS) of the CEAC cohort and the R-CEAC cohort were 73% (95% CI 61%-89%) versus 61% (95% CI 47%-79%) (HR 1.706, 95%CI 0.774–3.763, <i>P</i> = 0.178). The 3-year overall survival (OS) of the CEAC cohort and the R-CEAC cohort were both 79% (95% CI 67%-93%) (HR 1.083, 95%CI 0.418–2.808, <i>P</i> = 0.869). And 3-year cumulative incidence of relapse (CIR) was 21% (95% CI 6.8%-33%) and 38% (95% CI 18%-50%) (HR 1.842, 95%CI 0.779–4.339, <i>P</i> = 0.162) in the CEAC cohort and the R-CEAC cohort. For the safety profile, no difference was observed in adverse events. In conclusion, the addition of rituximab to the CEAC conditioning regimen did not improve survival outcomes and is not recommended for DLBCL patients undergoing ASCT.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Addition of rituximab to CEAC conditioning for autologous hematopoietic stem cell transplantation provides no survival benefit in diffuse large B-Cell lymphoma: A propensity score-matched cohort study

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年2月3日

查看全文
  • Chaoshuai Fan,
  • Jiabang Yang,
  • Yanni Peng,
  • Juan Hu,
  • Mingyue Cao,
  • Ruobing Li,
  • Dongmei Jiang,
  • Tao Wang,
  • Wen Luo,
  • Li Chen,
  • Yanrong Luo,
  • Guihua Lu

摘要

High dose chemotherapy followed by autologous hematopoietic stem cell transplantation (ASCT) is the standard of care for relapsed or refractory diffuse large B-cell lymphoma (DLBCL). Rituximab has significantly improved outcomes of DLBCL patients when incorporated into first-line or second-line chemotherapy. However, whether its addition to conditioning regimens further improves efficacy remains controversial. In this study, we explored the efficacy and safety of Rituximab with CEAC conditioning, a regimen previously reported by our center. We compared the CEAC regimen with or without Rituximab in 80 DLBCL patients with propensity score matching method at a ratio of 1:1 (40 CEAC, 40 R-CEAC). The objective response rate (ORR) was 95% in the CEAC cohort compared to 93% in the R-CEAC cohort (P = 0.615). The complete response (CR) rate was 70% versus 60%, respectively (P = 0.348). The 3-year progression-free survival (PFS) of the CEAC cohort and the R-CEAC cohort were 73% (95% CI 61%-89%) versus 61% (95% CI 47%-79%) (HR 1.706, 95%CI 0.774–3.763, P = 0.178). The 3-year overall survival (OS) of the CEAC cohort and the R-CEAC cohort were both 79% (95% CI 67%-93%) (HR 1.083, 95%CI 0.418–2.808, P = 0.869). And 3-year cumulative incidence of relapse (CIR) was 21% (95% CI 6.8%-33%) and 38% (95% CI 18%-50%) (HR 1.842, 95%CI 0.779–4.339, P = 0.162) in the CEAC cohort and the R-CEAC cohort. For the safety profile, no difference was observed in adverse events. In conclusion, the addition of rituximab to the CEAC conditioning regimen did not improve survival outcomes and is not recommended for DLBCL patients undergoing ASCT.